Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an update.
On October 20, 2025, XORTX Therapeutics Inc. announced it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares were below US$1.00 for 30 consecutive business days. This notification does not currently affect the company’s Nasdaq listing, and XORTX has 180 days to regain compliance. The company is exploring options to address this issue, while its TSX Venture Exchange listing remains unaffected.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease and gout. The company has three clinically advanced products in development, including XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney and organ injury associated with respiratory virus infections. Additionally, XORTX is working on a pre-clinical stage program, XRx-225, for Type 2 diabetic nephropathy, targeting aberrant purine metabolism and xanthine oxidase to reduce uric acid production.
Average Trading Volume: 10,664
Technical Sentiment Signal: Sell
Current Market Cap: C$5.73M
For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.